Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation

Hofmann-Winkler et al., Critical Care Explorations, doi:10.1097/CCE.0000000000000284

Nov 2020

Source PDF All Studies Meta AnalysisMeta

Retrospective 11 critically ill COVID-19 ICU patients with organ failure treated with camostat mesylate (6 patients) or HCQ (5 patients). Over an 8 day period, the severity of COVID-19 decreased in the camostat group as measured by a decline in the SOFA score, inflammatory markers, and improvement in oxygenation. A similar effect was not seen in the HCQ group.

Although the 58% lower mortality is not statistically significant, it is consistent with the significant 51% lower mortality [17‑71%] from meta analysis of the 8 mortality results to date.

Important missing comments or errors? Let us know.

Study covers camostat and HCQ.

risk of death, 58.3% lower, RR 0.42, p = 0.55, treatment 1 of 6 (16.7%), control 2 of 5 (40.0%), NNT 4.3.

ICU time, 61.1% lower, relative time 0.39, treatment 6, control 5.

SOFA, 55.6% lower, RR 0.44, treatment 6, control 5, day 8.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Hofmann-Winkler et al., 16 Nov 2020, retrospective, Germany, peer-reviewed, 19 authors, study period March 2020 - May 2020, this trial compares with another treatment - results may be better when compared to placebo.

This Paper Camostat All

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation

PhD Heike Hofmann-Winkler, MD Onnen Moerer, MD Sabine Alt-Epping, MD Anselm Bräuer, MD Benedikt Büttner, MD Martin Müller, Torben Fricke, Julian Grundmann, MD Lars-Olav Harnisch, MD Daniel Heise, Andrea Kernchen, MD Meike Pressler, MD Caspar Stephani, MD Björn Tampe, PhD Artur Kaul, Sabine Gärtner, Stefanie Kramer, PhD Stefan Pöhlmann, Martin Sebastian Winkler

Critical Care Explorations, doi:10.1097/cce.0000000000000284

Objectives: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown. Design: Retrospective observational case series. Setting: Patient treated in ICU of University hospital Göttingen, Germany. Patients: Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU. Interventions: Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group). Measurements and Main Results: Clinical courses were assessed by Sepsis-related Organ Failure Assessment score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ Failure Assessment score decreased in the camostat group but remained elevated in the hydroxychloroquine group. The decline in disease severity in camostat mesylate treated patients was paralleled by a decline in inflammatory markers and improvement of oxygenation. Conclusions: The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials.

References

Bardou, Menou, François, Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis, Am J Respir Crit Care Med

Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, New Engl J Med

Corman, Landt, Kaiser, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill

Das, Bhowmick, Tiwari, An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19), Clin Drug Investig

Gibo, Ito, Kawabe, Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity, Lab Invest

Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell

Hoffmann, Mösbauer, Hofmann-Winkler, Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature

Iwata-Yoshikawa, Okamura, Shimizu, TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection, J Virol

Maisonnasse, Guedj, Contreras, Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates, Nature

Puelles, Lütgehetmann, Lindenmeyer, Multiorgan and renal tropism of SARS-CoV-2, N Engl J Med

Wu, Wang, Kuo, An update on current therapeutic drugs treating COVID-19, Curr Pharmacol Rep, doi:10.1007/s40495-020-00216-7

Zhou, Vedantham, Lu, Protease inhibitors targeting coronavirus and filovirus entry, Antiviral Res

Zhu, Zhang, Wang, China Novel Coronavirus Investigating and Research Team: A novel coronavirus from patients with pneumonia in China, N Engl J Med

{ 'indexed': {'date-parts': [[2024, 8, 6]], 'date-time': '2024-08-06T12:35:20Z', 'timestamp': 1722947720476}, 'reference-count': 13, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '11', 'license': [ { 'start': { 'date-parts': [[2020, 11, 1]], 'date-time': '2020-11-01T00:00:00Z', 'timestamp': 1604188800000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '\n' ' Objectives:\n' ' Severe acute respiratory syndrome coronavirus 2 cell entry depends on ' 'angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell ' 'culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat ' 'mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently ' 'unknown.\n' ' \n' ' \n' ' Design:\n' ' Retrospective observational case series.\n' ' \n' ' \n' ' Setting:\n' ' Patient treated in ICU of University hospital Göttingen, ' 'Germany.\n' ' \n' ' \n' ' Patients:\n' ' Eleven critical ill coronavirus disease 2019 patients with organ failure ' 'were treated in ICU.\n' ' \n' ' \n' ' Interventions:\n' ' Compassionate use of camostat mesylate (six patients, camostat group) or ' 'hydroxychloroquine (five patients, hydroxychloroquine group).\n' ' \n' ' \n' ' Measurements and Main Results:\n' ' Clinical courses were assessed by Sepsis-related Organ Failure Assessment ' 'score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were ' 'determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and ' 'hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ ' 'Failure Assessment score decreased in the camostat group but remained elevated in the ' 'hydroxychloroquine group. The decline in disease severity in camostat mesylate treated ' 'patients was paralleled by a decline in inflammatory markers and improvement of ' 'oxygenation.\n' ' \n' ' \n' ' Conclusions:\n' ' The severity of coronavirus disease 2019 decreased upon camostat mesylate ' 'treatment within a period of 8 days and a similar effect was not observed in patients ' 'receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within ' 'randomized clinical trials.\n' ' ', 'DOI': '10.1097/cce.0000000000000284', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 17]], 'date-time': '2020-11-17T17:53:24Z', 'timestamp': 1605635604000}, 'page': 'e0284', 'source': 'Crossref', 'is-referenced-by-count': 38, 'title': 'Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation', 'prefix': '10.1097', 'volume': '2', 'author': [ { 'given': 'Heike', 'family': 'Hofmann-Winkler', 'sequence': 'first', 'affiliation': [ { 'name': 'Infection Biology Unit, German Primate Center-Leibniz Institute ' 'for Primate Research, Göttingen, Germany.'}]}, { 'given': 'Onnen', 'family': 'Moerer', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Sabine', 'family': 'Alt-Epping', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Anselm', 'family': 'Bräuer', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Benedikt', 'family': 'Büttner', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Martin', 'family': 'Müller', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Torben', 'family': 'Fricke', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Julian', 'family': 'Grundmann', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Lars-Olav', 'family': 'Harnisch', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Daniel', 'family': 'Heise', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Andrea', 'family': 'Kernchen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Meike', 'family': 'Pressler', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}, { 'given': 'Caspar', 'family': 'Stephani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Neurophysiology, University Medicine ' 'Göttingen, Göttingen, Germany.'}]}, { 'given': 'Björn', 'family': 'Tampe', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Nephrology and Rheumatology, University Medicine ' 'Göttingen, Göttingen, Germany.'}]}, { 'given': 'Artur', 'family': 'Kaul', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Biology Unit, German Primate Center-Leibniz Institute ' 'for Primate Research, Göttingen, Germany.'}]}, { 'given': 'Sabine', 'family': 'Gärtner', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Biology Unit, German Primate Center-Leibniz Institute ' 'for Primate Research, Göttingen, Germany.'}]}, { 'given': 'Stefanie', 'family': 'Kramer', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Biology Unit, German Primate Center-Leibniz Institute ' 'for Primate Research, Göttingen, Germany.'}]}, { 'given': 'Stefan', 'family': 'Pöhlmann', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infection Biology Unit, German Primate Center-Leibniz Institute ' 'for Primate Research, Göttingen, Germany.'}, { 'name': 'Faculty of Biology and Psychology, University Göttingen, ' 'Göttingen, Germany.'}]}, { 'given': 'Martin Sebastian', 'family': 'Winkler', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Emergency and Intensive Care ' 'Medicine, University of Göttingen, Göttingen, Germany.'}]}], 'member': '276', 'published-online': {'date-parts': [[2020, 11, 16]]}, 'reference': [ { 'key': 'R1-20231027', 'doi-asserted-by': 'crossref', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019.', 'volume': '382', 'author': 'Zhu', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'R2-20231027', 'doi-asserted-by': 'crossref', 'first-page': '271', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor.', 'volume': '181', 'author': 'Hoffmann', 'year': '2020', 'journal-title': 'Cell'}, { 'key': 'R3-20231027', 'doi-asserted-by': 'crossref', 'first-page': '591', 'DOI': '10.1007/s40261-020-00927-1', 'article-title': 'An updated systematic review of the therapeutic role of ' 'hydroxychloroquine in coronavirus disease-19 (COVID-19).', 'volume': '40', 'author': 'Das', 'year': '2020', 'journal-title': 'Clin Drug Investig'}, { 'key': 'R4-20231027', 'first-page': '1', 'article-title': 'An update on current therapeutic drugs treating COVID-19.', 'volume': '11', 'author': 'Wu', 'year': '2020', 'journal-title': 'Curr Pharmacol Rep'}, { 'key': 'R5-20231027', 'doi-asserted-by': 'crossref', 'first-page': '2000045', 'DOI': '10.2807/1560-7917.ES.2020.25.3.2000045', 'article-title': 'Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.', 'volume': '25', 'author': 'Corman', 'year': '2020', 'journal-title': 'Euro Surveill'}, { 'key': 'R6-20231027', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2019014', 'article-title': 'Hydroxychloroquine with or without azithromycin in mild-to-moderate ' 'Covid-19.', 'author': 'Cavalcanti', 'year': '2020 Jul 23', 'journal-title': 'New Engl J Med'}, { 'key': 'R7-20231027', 'doi-asserted-by': 'crossref', 'first-page': '588', 'DOI': '10.1038/s41586-020-2575-3', 'article-title': 'Chloroquine does not inhibit infection of human lung cells with ' 'SARS-CoV-2.', 'volume': '585', 'author': 'Hoffmann', 'year': '2020', 'journal-title': 'Nature'}, { 'key': 'R8-20231027', 'doi-asserted-by': 'crossref', 'first-page': '584', 'DOI': '10.1038/s41586-020-2558-4', 'article-title': 'Hydroxychloroquine use against SARS-CoV-2 infection in non-human ' 'primates.', 'volume': '585', 'author': 'Maisonnasse', 'year': '2020', 'journal-title': 'Nature'}, { 'key': 'R9-20231027', 'doi-asserted-by': 'crossref', 'first-page': '75', 'DOI': '10.1038/labinvest.3700203', 'article-title': 'Camostat mesilate attenuates pancreatic fibrosis via inhibition of ' 'monocytes and pancreatic stellate cells activity.', 'volume': '85', 'author': 'Gibo', 'year': '2005', 'journal-title': 'Lab Invest'}, { 'key': 'R10-20231027', 'doi-asserted-by': 'crossref', 'first-page': '847', 'DOI': '10.1164/rccm.201502-0299OC', 'article-title': 'Membrane-anchored serine protease matriptase is a trigger of pulmonary ' 'fibrogenesis.', 'volume': '193', 'author': 'Bardou', 'year': '2016', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': 'R11-20231027', 'doi-asserted-by': 'crossref', 'first-page': 'e01815', 'DOI': '10.1128/JVI.01815-18', 'article-title': 'TMPRSS2 contributes to virus spread and immunopathology in the airways ' 'of murine models after coronavirus infection.', 'volume': '93', 'author': 'Iwata-Yoshikawa', 'year': '2019', 'journal-title': 'J Virol'}, { 'key': 'R12-20231027', 'doi-asserted-by': 'crossref', 'first-page': '590', 'DOI': '10.1056/NEJMc2011400', 'article-title': 'Multiorgan and renal tropism of SARS-CoV-2.', 'volume': '383', 'author': 'Puelles', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'R13-20231027', 'doi-asserted-by': 'crossref', 'first-page': '76', 'DOI': '10.1016/j.antiviral.2015.01.011', 'article-title': 'Protease inhibitors targeting coronavirus and filovirus entry.', 'volume': '116', 'author': 'Zhou', 'year': '2015', 'journal-title': 'Antiviral Res'}], 'container-title': 'Critical Care Explorations', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/CCE.0000000000000284', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 10, 27]], 'date-time': '2023-10-27T20:12:08Z', 'timestamp': 1698437528000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/CCE.0000000000000284'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 11]]}, 'references-count': 13, 'journal-issue': {'issue': '11', 'published-online': {'date-parts': [[2020]]}}, 'URL': 'http://dx.doi.org/10.1097/CCE.0000000000000284', 'relation': {}, 'ISSN': ['2639-8028'], 'subject': [], 'published': {'date-parts': [[2020, 11]]}}

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0